Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)
Servizos
Servizos
Data de publicación
2015Título da revista
EUROPEAN JOURNAL OF CANCER
Tipo de contido
Publicación de congreso
